Rimegepant: A Breakthrough for Preventing Menstrual Migraines

Research Summary

Researchers discovered that rimegepant effectively prevents perimenstrual migraines when used on a short-term basis. The study, published in The Journal of Headache and Pain, highlighted that rimegepant, a calcitonin gene-related peptide receptor antagonist, significantly reduced the frequency of migraines during the perimenstrual period. Participants who received rimegepant experienced fewer migraines compared to those given a placebo, demonstrating its potential as a preventive treatment. The researchers emphasized that these findings could offer a new option for women seeking to manage migraines associated with their menstrual cycle, provided that further studies confirm its long-term efficacy and safety.

Study Details

📄 Title: Short-term prevention of perimenstrual migraine with rimegepant.

👥 Research Team: Frank F et al.

📚 Published In: J Headache Pain

📅 Publication Date: 2025 Nov 12

⚕️ Medical Disclaimer: This summary is generated automatically from recent migraine research. Always consult with healthcare professionals for medical advice.